-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche Obtains US FDA Approval for Oral Breast Cancer Drug Wilserdly

MT Newswires·11/16/2026 23:27:41
Listen to the news
11:27 PM EST, 11/16/2026 (MT Newswires) -- Roche (RO.SW) received approval from the US Food and Drug Administration for its oral drug Wilserdly plus everolimus to treat certain breast cancer patients. Wilserdly, or giredestrant, is approved for adults with estrogen receptor-positive human epidermal growth factor receptor 2-negative ESR1-mutated locally advanced or metastatic breast cancer, according to a Monday release. It is indicated for patients whose disease has recurred or metastasized while undergoing or after endocrine-based adjuvant therapy. The decision was based on positive data from the phase 3 evERA breast cancer study, in which the combination significantly extended progression-free survival and lowered the risk of disease progression or death by 62%, compared with standard endocrine therapy plus everolimus. Wilserdly is also under FDA priority review as an adjuvant treatment for intermediate- to high-risk ER-positive, HER2-negative, stage 1, 2, and 3 breast cancer, with a decision expected by Nov. 30.